Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE (NCT06892145) | Clinical Trial Compass
RecruitingPhase 1
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
China12 participantsStarted 2025-06-12
Plain-language summary
This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the efficacy of MC-1-50 cell preparation in patients with refractory SLE, and to explore the applicable dose regimen for phase II clinical trials.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The patient or their guardian agrees to participate in this clinical trial and sign the ICF, indicating their understanding of the purpose and procedures of this clinical trial and willingness to participate in the study;
✓. Age ≥ 18 years old , gender not limited;
✓. Patients diagnosed with SLE according to the 2019 EULAR/ACR classification criteria,And by hydroxychloroquine, sufficient glucocorticoid (≥1mg/kg/d prednisone or equivalent amount of other hormones), to less than 2Treatment with immunosuppressants (including cyclophosphamide, motecophanate, azathioprine, methotrexate, cyclosporine, tacrolimus, sirolimus, leflunomide, etc.), and at least one approved biological agent (including titacept, Beliuzumab, etc.), with a total duration of treatment ≥3 months, still in a disease active state, or unable to tolerate conventional therapy;
✓. SLEDAI-2K score ≥7 points;
✓. Autoantibody test results are positive: ANA antibody positive and/or serum anti-DSDNA positive;
✓. Adequate renal, hepatic, pulmonary and cardiac function defined as:
. Acute severe nephritis: had or was undergoing renal replacement therapy within 3 months prior to reinfusion, or had significant renal deterioration that the investigator believed was likely to cause the subject to require high doses of corticosteroids (prednisone ≥1mg/kg/ day or equivalent of other hormones), cyclophosphamide, or mycophanate during the first 3 months of the study;Clinical stable lupus nephritis that can be controlled during screening can be considered;
✕. There were other lupus crises that were not controlled at the time of screening;
✕. Individuals who have received CAR-T therapy or other gene modified cell therapies;
✕. Combined with other autoimmune diseases requiring systemic treatment;
✕. HBsAg or HBcAb positive and HBV DNA test greater than the normal range;HCV antibody positive and HCV RNA detection greater than the normal range;HIV antibody positive;Treponema pallidum antibody positive;
✕. Suffered from any of the following heart diseases:
✕. New York Heart Association (NYHA) stage III or IV congestive heart failure;